In part 7 of this Exclusive Interview, Dr. Carla Greenbaum talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about a diabetes vaccine and past efforts to treat those at risk.
Carla Greenbaum, MD is Director of the Diabetes Research Program at Benaroya Research Institute at Virginia Mason in Seattle, WA.
Transcript of this video segment:
Steve Freed: I know there’s research going on right now about developing a vaccine. How far do you think that’s going to progress? I mean from your personal experience?
Carla Greenbaum: You know I think in terms of a vaccine when people talk about it, I think they’re mostly imaging the idea of soon after somebody’s born, before antibodies are developed can we do what we call primary prevention or actually even stop antibodies beforehand. And there’s a lot of work going into it. We haven’t seen fruits of that yet. Someday I hope that will be the answer.
Steve Freed: I know they’ve done studies to people that are at risk that gives them insulin and that didn’t show very positive results. I think that was a couple years ago.
Carla Greenbaum: Right actually in the 1990’s we did a study called the Diabetes Prevention Trial or DPT1, and we had two actually different trials. One trial was using injections of insulin. The idea was that we could rest the beta cells and they would survive the immunotech better. Unfortunately, that wasn’t effective. We did a second trial using oral insulin. Now you know of all people that taking oral insulin doesn’t affect your blood sugars at all, but what it does is that it decreases the immune response. Just imagine the kid, right, the kids on the floor are eating dirt or my kids did, you know they crawl around, and when you eat that, your gut’s immune system down regulates the response, you don’t want to respond to everything. And so we take advantage of that by this notion of oral tolerance. So, the DPT1, the diabetes prevention trial oral insulin study tested that and overall the results were negative, right? It didn’t have an effect. However, there was a subgroup that had quite an effect. So, trial net has now repeated that study and those are the results that you’ll be hearing about soon.